FDA Approves VYLOY® with Chemotherapy for Biomarker Positive Gastric or GEJ Adenocarcinoma
ENHERTU® Effective Against Brain Metastases in Patients with HER2+ Breast Cancer
FDA Approves RYBREVANT® plus Chemotherapy for EGFR-Mutated NSCLC
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
TAGRISSO® after Chemoradiotherapy in Stage III EGFR Mutated Non-Small Cell Lung Cancer
Late Breaking Abstract – ASCO 2024: Sustained Improvement in Relapse Free Survival with Personalized mRNA Cancer Vaccine plus KEYTRUDA® in Resected High Risk Melanoma
Late Breaking Abstract – ASCO 2024: Subcutaneous versus Intravenous RYBREVANT® in Refractory EGFR Mutated Advanced NSCLC
Late Breaking Abstract – ASCO 2024: Long Term Outcomes with LORBRENA® in ALK-Positive Non Small Cell Lung Cancer
FDA Approves KRAZATI® with ERBITUX® for KRAS G12C-Mutated Colorectal Cancer
Late Breaking Abstract – ASCO 2024: KRAZATI® Superior to Docetaxel in KRAS G12C Mutated Non Small Cell Lung Cancer
Late Breaking Abstract – ASCO 2024: ENHERTU® Improves PFS in HR-Positive, HER2-Low and HER-Ultralow Metastatic Breast Cancer
Late Breaking Abstract – ASCO 2024: TAGRISSO® after Chemoradiotherapy in Stage III EGFR Mutated Non-Small Cell Lung Cancer
Late Breaking Abstract – ASCO 2024: SCEMBLIX® Superior to Other TKIs in Newly Diagnosed Chronic Myeloid Leukemia
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
FDA Approves ALECENSA® as Adjuvant Treatment for ALK-Positive Non Small Cell Lung Cancer
FDA Approves ENHERTU® for Unresectable or Metastatic HER2-Positive Solid Tumors
Novel Prognostic Factors for Treatment-Free Remission in Chronic Myeloid leukemia
FDA Approves RYBREVANT® in Combination with Chemotherapy for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
TUKYSA® Plus KADCYLA® in Advanced HER2-Positive Breast Cancer
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C